Exploration of sialic acid receptors as a potential target for cancer treatment: A comprehensive review

Ghosh, Meheli; Hazarika, Priyodarshini; Dhanya, S.J.; Pooja, Deep; Kulhari, Hitesh

doi:10.1016/j.ijbiomac.2023.128415

Cited by 2 publications

(1 citation statement)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes with glycoproteins like sialic acid and mannose target ovarian cancer cells, Integrins like α6β4 and α6β1 targets advanced NSCLC, αvβ5 targets advanced hepatic cancer and tetraspannin CD63 expressed exosome targets dendritic cells. [126][127][128] Exosomes with selective receptors like CD47 can evade host immunity, increasing the uptake ability. [129]…”

Section: Nano-biointeraction Of Eexmentioning

confidence: 99%

Transforming native exosomes to engineered drug vehicles: A smart solution to modern cancer theranostics

Sahoo,

Tripathi,

Biswal

et al. 2024

Biotechnology Journal

View full text Add to dashboard Cite

Exosomes have been the hidden treasure of the cell in terms of cellular interactions, transportation and therapy. The native exosomes (NEx) secreted by the parent cells hold promising aspects in cancer diagnosis and therapy. NEx has low immunogenicity, high biocompatibility, low toxicity and high stability which enables them to be an ideal prognostic biomarker in cancer diagnosis. However, due to heterogeneity, NEx lacks specificity and accuracy to be used as therapeutic drug delivery vehicle in cancer therapy. Transforming these NEx with their innate structure and multiple receptors to engineered exosomes (EEx) can provide better opportunities in the field of cancer theranostics. The surface of the NEx exhibits numeric receptors which can be modified to pave the direction of its therapeutic drug delivery in cancer therapy. Through surface membrane, EEx can be modified with increased drug loading potentiality and higher target specificity to act as a therapeutic nanocarrier for drug delivery. This review provides insights into promising aspects of NEx as a prognostic biomarker and drug delivery tool along with its need for the transformation to EEx in cancer theranostics. We have also highlighted different methods associated with NEx transformations, their nano‐bio interaction with recipient cells and major challenges of EEx for clinical application in cancer theranostics.

show abstract

Section: Nano-biointeraction Of Eexmentioning

confidence: 99%